NCT06571422View on ClinicalTrials.gov

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

May 15, 2026

Study Completion Date

April 30, 2027

Conditions
Advanced Malignant Solid Tumors
Interventions
DRUG

WJ47156

Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period

DRUG

JS001+Bevacizumab

Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.

DRUG

JS207

Participants in Cohort2 of combination therapy phase will receive WJ47156 plus JS207. JS207 is administered intravenously.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER